Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial [Original Articles]

Conclusions— In patients with HF and reduced EF enrolled in PARADIGM-HF, LVEF was a significant and independent predictor of all outcomes. Sacubitril/valsartan was effective at reducing cardiovascular death and HF hospitalization throughout the LVEF spectrum. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.

http://circheartfailure.ahajournals.org/cgi/content/short/9/3/e002744?rss=1

Source: Circulation: Heart Failure - February 25, 2016 Category: Cardiology Authors: Solomon, S. D., Claggett, B., Desai, A. S., Packer, M., Zile, M., Swedberg, K., Rouleau, J. L., Shi, V. C., Starling, R. C., Kozan, O., Dukat, A., Lefkowitz, M. P., McMurray, J. J. V. Tags: Heart Failure Original Articles Source Type: research